13F Data
13F filer · CIK 2039349

GordonMD Global Investments LP

Beverely Hills, CA · filing since Q4 2025 · last filing Aug 14, 2026
Reported value
$206.7M
+$63.1M vs prior
Positions
16
New / sold out
1 / 1
Added / reduced
4 / 2
Turnover
2.9%
buys $47.8M · sells $5.2M
Top-10 weight
83.9%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
AddedPYXIS ONCOLOGY INC+5,903,039+143.2%+$17.8M
NewEDITAS MEDICINE INC+3,127,000–+$10.1M
AddedALLOGENE THERAPEUTICS INC+3,868,000+270.5%+$8.0M
AddedTEVA PHARMACEUTICAL INDS LTD+1,145,000+91.1%+$7.8M
AddedCELLDEX THERAPEUTICS INC NEW+109,413+64.2%+$4.1M

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
Sold outTARSUS PHARMACEUTICALS INC-42,680-100.0%$-3.0M
ReducedVIR BIOTECHNOLOGY INC-165,000-10.9%$-1.7M
ReducedTAYSHA GENE THERAPIES INC-14,365-1.9%$-486.7K

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2025: $139.5MQ1 2026: $143.6MQ2 2026: $206.7M
Q4 2025Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1KYVERNA THERAPEUTICS INCCOM4,244,818$37.8M18.30%
2PYXIS ONCOLOGY INCCOMMON STOCK10,024,909$30.2M14.60%
3TAYSHA GENE THERAPIES INCCOM SHS723,185$24.5M11.86%
4TEVA PHARMACEUTICAL INDS LTDSPONSORED ADS2,402,495$16.4M7.92%
5VIR BIOTECHNOLOGY INCCOM1,353,552$13.8M6.67%
6ALLOGENE THERAPEUTICS INCCOM5,298,000$11.0M5.33%
7CELLDEX THERAPEUTICS INC NEWCOM NEW279,720$10.4M5.04%
8EDITAS MEDICINE INCCOM3,127,000$10.1M4.90%
9ULTRAGENYX PHARMACEUTICAL INCOM289,101$9.7M4.67%
10BAUSCH PLUS LOMB CORPCOMMON SHARES573,472$9.5M4.60%
6 more rows. Subscribe for $29/month to see every row, download the data and use the API.